Kura Oncology (NASDAQ:KURA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on ...

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS ...

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision ...

Investing.com — Kura Oncology, Inc. (KURA)股价已触及52周低点，跌至6.75美元，这家生物制药公司正面临充满挑战的市场环境。根据 InvestingPro 数据显示，该公司保持强劲的流动性，流动比率为9.46，且资产负债表上的现金多于债务，在市场动荡中提供了一定的稳定性。这一价格水平反映了与去年相比的显著下跌，股票一年内变化率为-69.52%。投资者正密切 ...